Literature DB >> 8166890

Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats.

P A Cossum1, H Sasmor, D Dellinger, L Truong, L Cummins, S R Owens, P M Markham, J P Shea, S Crooke.   

Abstract

5'-TTGCTTCCATCTTCCTCGTC-3' (ISIS 2105) is a phosphorothioate oligodeoxynucleotide currently being evaluated as an intralesional antiviral drug for the treatment of genital warts that are caused by the human papillomavirus. ISIS 2105, labeled with 14C (at the carbon-2 position of thymine) was administered as a single i.v. injection (3.6 mg/kg) to female Sprague-Dawley rats to assess the disposition of the drug. After i.v. administration of [14C]2105, blood radioactivity disappeared in a multiexponential manner with the half-lives of the phases equal to 0.4, 1.9, 7.1 and 5.1 hr. The initial volume of distribution was 22 ml and the postdistribution volume of distribution was 1076 ml, which indicated an extensive distribution of radioactivity. The apparent blood clearance was 14.7 ml/hr. The radioactivity in the expired air accounted for 51% of the administered dose over the 10-day period. Urinary and fecal radioactivity accounted for 15% and 5% of the administered dose, respectively. The major sites of radioactivity uptake were the liver (up to 22.6% of the dose), kidneys (renal cortex, up to 14% of the dose), bone marrow (up to 14% of the dose), skin (up to 13% of the dose) and skeletal muscle (up to 9% of the dose). Other tissues contained approximately 1% or less of the dose. The overall recovery of radioactivity 10 days postdosing was 95.1 +/- 7.5% (mean +/- S.D.) of the administered single dose. The radioactivity in the blood was almost completely in the plasma during the course of the study. In the plasma, the radioactivity was extensively bound to proteins, as assessed by size-exclusion high-performance liquid chromatography (HPLC), in samples up to 8 hr postdosing. Retention data on size-exclusion HPLC and in vitro incubations using purified proteins suggested that the plasma proteins that bound [14C]2105 were albumin and alpha 2-macroglobulin. The complex formed between the plasma proteins and [14C]2105-derived radioactivity was dissociated on anion-exchange HPLC to indicate that the great majority of plasma radioactivity coeluted with intact [14C]2105 in samples that contained sufficient radioactivity for analysis. There was a time-dependent decrease in the proportion of hepatic and renal radioactivity that coeluted with the intact [14C]2105 during the course of the study. The urine did not contain radioactivity that eluted with intact [14C]2105 on anion-exchange HPLC.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8166890

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Preclinical and clinical pharmacology of antisense oligonucleotides.

Authors:  E G Marcusson; B R Yacyshyn; W R Shanahan; N M Dean
Journal:  Mol Biotechnol       Date:  1999-08       Impact factor: 2.695

2.  A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices.

Authors:  Xiaohui Wei; Guowei Dai; Guido Marcucci; Zhongfa Liu; Dale Hoyt; William Blum; Kenneth K Chan
Journal:  Pharm Res       Date:  2006-05-25       Impact factor: 4.200

Review 3.  shRNA and siRNA delivery to the brain.

Authors:  William M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2007-03-16       Impact factor: 15.470

4.  Metabolism of GTI-2040, a phosphorothioate oligonucleotide antisense, using ion-pair reversed phase high performance liquid chromatography (HPLC) coupled with electrospray ion-trap mass spectrometry.

Authors:  Xiaohui Wei; Guowei Dai; Zhongfa Liu; Hao Cheng; Zhiliang Xie; Guido Marcucci; Kenneth K Chan
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 5.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

6.  Cytosolic malate dehydrogenase confers selectivity of the nucleic acid-conducting channel.

Authors:  Basil Hanss; Edgar Leal-Pinto; Avelino Teixeira; Robert E Christian; Jeffery Shabanowitz; Donald F Hunt; Paul E Klotman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

7.  Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): comparison with other delivery routes.

Authors:  P L Nicklin; D Bayley; J Giddings; S J Craig; L L Cummins; J G Hastewell; J A Phillips
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

8.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

9.  In vivo suppression of the renal Na+/Pi cotransporter by antisense oligonucleotides.

Authors:  R Oberbauer; G F Schreiner; J Biber; H Murer; T W Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.

Authors:  Hyunmin Kang; Md Rowshon Alam; Vidula Dixit; Michael Fisher; Rudy L Juliano
Journal:  Bioconjug Chem       Date:  2008-11-19       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.